Stocktoria
BioNexus Gene Lab Corp BGLC
BioNexus Gene Lab Corp (BGLC) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $7.4M at a -40.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.29 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.533 |
| Retained earnings / assets | -0.695 |
| EBIT / assets | -0.32 |
| Equity / liabilities | 13.506 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BGLC | BioNexus Gene Lab Corp | 4/9 | 13.26 | — | — |
| YDES | YD Bio Ltd | 1/9 | -1.35 | — | — |
| SERA | SERA PROGNOSTICS, INC. | 2/9 | -8.32 | — | — |
| ACON | Aclarion, Inc. | 4/9 | 4.23 | — | — |
| CFOR | CapForce Inc. | 2/9 | -14.09 | 1 | — |
| XGN | EXAGEN INC. | 3/9 | -14.91 | — | +19.7% |
| PSNL | Personalis, Inc. | 3/9 | 0.31 | — | -17.7% |
About BioNexus Gene Lab Corp
BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company's products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
FAQ
Is BGLC financially healthy?
BioNexus Gene Lab Corp's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does BGLC pay a dividend?
No, BioNexus Gene Lab Corp does not currently pay a dividend.
How profitable is BGLC?
In FY2025, BioNexus Gene Lab Corp had a net margin of -40.2% and a return on equity of -34.6%.
Is BGLC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on BioNexus Gene Lab Corp: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.